Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in Patients With Keloid
NCT06373458Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ritlecitinib tosilate in keloid, sponsored by Icahn School of Medicine at Mount Sinai. Started Aug 2024; status: recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
keloid
Beyond the preview
Go deeper on NCT06373458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373458.